

LIST OF TABLES

1.1 List of Tables

Table 1:Symptoms of AD

Table 2:Guidelines for the Treatment of AD

Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012

Table 4:Leading Branded Treatments for AD, 2013

Table 5:Product Profile - Aricept

Table 6:Aricept SWOT Analysis, 2013

Table 7:Product Profile- Exelon

Table 8:Exelon SWOT Analysis, 2012

Table 9:Product Profile - Razadyne

Table 10:Razadyne SWOT Analysis, 2013

Table 11:Product Profile- Namenda

Table 12:Namenda SWOT Analysis, 2013

Table 13:Overall Unmet Needs - Current Level of Attainment

Table 14:Clinical Unmet Needs - Gap Analysis, 2013

Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012

Table 16:Comparison of Therapeutic Classes in Development for AD, 2013

Table 17:Comparison of Therapeutic Classes in Development for AD, 2013

Table 18:Product Profile - Arimenda

Table 19:Arimenda SWOT Analysis, 2013

Table 20:Product Profile - Gammagard Liquid 10%

Table 21:Product Profile - Solanezumab

Table 22:Solanezumab SWOT Analysis, 2013

Table 23:Product Profile - Gantenerumab

Table 24:Gantenerumab SWOT Analysis, 2013

Table 25:Product Profile - Crenezumab

Table 26:Crenezumab SWOT Analysis, 2013

Table 27:Product Profile - TRx0237

Table 28:TRx0237 SWOT Analysis, 2013

Table 29:Product Profile - MK-8931

Table 30:MK-8931 SWOT Analysis, 2013

Table 31:Product Profile - EVP-6124

Table 32:EVP-6124 SWOT Analysis, 2013

Table 33:Product Profile - Lu AE58054

Table 34:Lu AE58054 SWOT Analysis, 2013

Table 35:Sales Forecasts (\$m) for AD in Germany, 2012-2022

Table 36:Key Events Impacting Sales for AD in Germany, 2012-2022

Table 37:AD Market in Germany - Drivers and Barriers, 2012-2022

Table 38:Key Launch Dates

Table 39:Key Patent Expirations

1.2 List of Figures

Figure 1: Atrophy of the Brain in AD

Figure 2: Key Pathological Features in AD Versus a Healthy Neuron

Figure 3: Non-Amyloidogenic Metabolism of APP

Figure 4: Amyloidogenic Metabolism of APP

Figure 5: Neurofibrillary Tangles

Figure 6: Oxidative Damage Due to Free Radicals

Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013

Figure 8: AD - Pipeline Drugs by Target, 2012

Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022

Figure 10: Sales for AD in the Germany by Drug Class, 2012-2022